Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16624840 | 0.98 | KMT2A (0.64) | KMT2AMEN1RECQLRAB9APABPC1 | |
| Hydrochloric Acid SCHEMBL10526733 | 0.97 | KMT2A (0.62) | KMT2AMEN1RECQLRAB9APABPC1 | |
| Bromide SCHEMBL10529434 | 0.86 | POLB (0.52) | KMT2AMEN1RECQLRAB9APABPC1 | |
| Bromide SCHEMBL10528569 | 0.86 | POLB (0.67) | KMT2AMEN1RECQLPABPC1ATM | |
| Bromide SCHEMBL3845991 | 0.85 | SMN1; SMN2 (0.52) | KMT2AMEN1RECQLRAB9AALDH1A1 | |
| Bromide SCHEMBL3850914 | 0.85 | KMT2A (0.52) | KMT2AMEN1RECQLRAB9APABPC1 | |
| Bromide SCHEMBL10529210 | 0.85 | POLB (0.51) | KMT2AMEN1RECQLRAB9APABPC1 | |
| SCHEMBL10531142 | 0.84 | POLB (0.64) | KMT2AMEN1RECQLRAB9APABPC1 | |
| Bromide SCHEMBL10528590 | 0.84 | KMT2A (0.49) | KMT2AMEN1RECQLPABPC1ATM | |
| Bromide SCHEMBL3849692 | 0.83 | NPSR1 (0.51) | KMT2AMEN1RECQLRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1213282-A1 | Substituted imidazolium salts and their use for the inhibition of protein ageing. | ALTEON Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2018149672-A1 | TWO-COMPONENT POLYURETHANE COMPOSITION COMPRISING A LATENT CATALYST | HENKEL AG & CO. KGAA (DE) | 2018-08-23 | — | — | WO | disclosed |
| EP-3363840-A1 | TWO-COMPONENT POLYURETHANE COMPOSITION COMPRISING A LATENT CATALYST | Henkel AG & Co. KGaA (DE) | 2018-08-22 | — | — | EP | disclosed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040198795-A1 | Substituted imidazoliums and methods of use therefor | SYNVISTA THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | ALTEON, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| EP-1213282-A1 | Substituted imidazolium salts and their use for the inhibition of protein ageing. | ALTEON Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | KMT2A 4599/4885MEN1 1999/4885RECQL 2147/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | KMT2A 4535/4885MEN1 1815/4885RECQL 866/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | KMT2A 4545/4885MEN1 2481/4885RECQL 2158/4885 |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, COL2A1 | KMT2A 4051/4885MEN1 494/4885RECQL 1540/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | KMT2A 4493/4885MEN1 3331/4885RECQL 2714/4885 |
| US-20040198795-A1 | Substituted imidazoliums and methods of use therefor | AGER, NOTUM, IDE | KMT2A 3518/4885MEN1 4151/4885RECQL 4089/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | KMT2A 4326/4885MEN1 2134/4885RECQL 1463/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | KMT2A 4075/4885MEN1 515/4885RECQL 1439/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | KMT2A 4520/4885MEN1 3327/4885RECQL 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.